Are there any upcoming equity offerings or dilution events associated with the new appointments?

Answer to the Question

The corporate‑update press release does not mention any planned equity issuance, private placement, rights offering, or other dilutive transaction tied to the newly‑appointed directors. In the language of the filing there is no reference to a “planned offering,” “share‑sale,” “capital raise,” or “stock‑based compensation” that would immediately increase the outstanding share count. Consequently, based on the information currently disclosed, there is no confirmed dilution event associated with the appointments.

Trading Implications

Because no official offering has been announced, the market is likely pricing the appointment news on the perceived strategic value of the new directors—deep marketing and AI expertise—rather than on a supply‑side shock to the share base. The absence of an announced capital raise keeps the current float (≈ 13 M shares on the OTCQB) unchanged, meaning any upside or downside will be driven primarily by perception of the board’s ability to accelerate growth (potentially leading to future funding needs) and by standard price‑action dynamics. Traders should monitor the company’s upcoming SEC filings (e.g., Form 8‑K, S‑1, or S‑3) for any “capital‑raising” language and watch for a rise in insider‑sell or purchase activity, which can be early clues of a forthcoming offering. In the meantime, the stock’s technical picture (e.g., trading near its 20‑day moving average with modest upward momentum) suggests a modest‑risk long bias if you believe the new directors will materially enhance the business, but keep a watch‑list for any dilution‑related filing in the next 30‑45 days.